💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Sulfisoxazole

CHEMBL453 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
267.3 g/mol
LogP
1.0
Phase
4

Sulfisoxazole is a short-acting sulfonamide antibiotic with high urinary and tissue concentrations, used for the treatment of urinary tract infections, acute otitis media (in combination with erythromycin), and nocardiosis caused by susceptible organisms. It achieves higher free drug concentrations in urine than many sulfonamides due to lower plasma protein binding, making it particularly effective for urinary infections. Combination with erythromycin was previously used for penicillin-allergic patients with acute otitis media.

น้ำหนักโมเลกุล

267.3100 g/mol

LogP

1.00

TPSA

107.00 Ų

Lipinski RO5

ผ่าน

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C

                

                

                
                

                    
InChI

                    
InChI=1S/C11H13N3O3S/c1-7-8(2)13-17-11(7)14-18(15,16)10-5-3-9(12)4-6-10/h3-6,14H,12H2,1-2H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C11H13N3O3S

                    

                    
                    

                        
HBD / HBA

                        
2 / 6

                    

                    
                    

                        
พันธะที่หมุนได้

                        
3

                    

                    
                    
                    

                        
อะตอมหนัก

                        
18

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
คำถามที่พบบ่อย

                

                    
                    

                        
                        

                            
Sulfisoxazole is a short-acting sulfonamide antibiotic with high urinary and tissue concentrations, used for the treatment of urinary tract infections, acute otitis media (in combination with erythromycin), and nocardiosis caused by susceptible organisms. It achieves higher free drug concentrations in urine than many sulfonamides due to lower plasma protein binding, making it particularly effective for urinary infections. Combination with erythromycin was previously used for penicillin-allergic patients with acute otitis media.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Sulfisoxazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL453.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5344.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
ข้อจำกัดความรับผิดชอบทางการแพทย์

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.